Hannes Snellman has Advised Oasmia Pharmaceutical AB in Connection with Entering a Global Strategic Partnership with Elevar Therapeutics Inc
27 March 2020
Hannes Snellman has advised Oasmia Pharmaceutical AB, listed on Nasdaq Stockholm, Mid Cap, on corporate, disclosure, governance and due diligence matters in connection with Oasmia entering a global strategic partnership with US based Elevar Therapeutics Inc. Hannes Snellman has in this connection also assisted Oasmia and its global/US pharmaceutical counsel. The agreement includes milestone payments with a potential of up to USD 678 million depending on Elevar’s achievement of future sales milestones, clinical development milestones and regulatory approval milestones. Elevar will also pay Oasmia double-digit royalties on sales of Apealea® and USD 20 million as an upfront payment.